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Background: Lipoprotein (a) (Lp [a]) is known being correlated with coronary artery disease (CAD). The SLC22A3-
LPAL2-LPA gene cluster, relating with modulating the level of plasma Lp (a), has recently been reported to be
associated with CAD in Caucasians. The purpose of this study was to verify whether this finding can be expanded
to the Chinese Han population.
Methods and Results: Using a Chinese Han sample, which consisted of 1012 well-characterized CAD patients and
889 healthy controls, we tested the associations of four SNPs (rs2048327, rs3127599, rs7767084 and rs10755578) in
the SLC22A3-LPAL2-LPA gene cluster, and their inferred haplotypes with the risk of CAD. Allelic, genotypic and
haplotype association analyses all showed that the gene cluster was not associated with CAD in this Chinese Han
sample.
Conclusions: We for the first time explored the association of the four SNPs in the SLC22A3-LPAL2-LPA gene cluster
with CAD in a large Chinese Han sample. Nevertheless, this study did not reveal any significant evidence of this
gene cluster to increase the risk of CAD in this population.
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Coronary artery disease (CAD) is now widespread and
becoming a heavy burden for both developed and devel-
oping countries. A long list of susceptibility loci for
CAD has been identified in previous genetic studies.
Most recently, the gene cluster aligned by solute carrier
family 22 member 3 (SLC22A3), lipoprotein(a)-like 2
(LPAL2), and lipoprotein(a) (LPA), known as SLC22A3-
LPAL2-LPA on chromosome 6q26-27, attracted much
attention, possibly due to its capability to regulate the
plasma level of lipoprotein(a) (Lp(a)) [1].* Correspondence: grace198033@126.com
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reproduction in any medium, provided the orLp(a), a low-density lipoprotein (LDL)-like particle
synthesized in the liver [2], has been well known as an
independent risk factor for CAD [3-6]. Its protein com-
ponent-apolipoprotein(a)[apo(a)], accounts for 91% vari-
ation of the plasma Lp(a) concentration [7]. LPA, one
member of the SLC22A3-LPAL2-LPA gene cluster,
encodes apo(a) [5], and is associated with Lp(a) levels,
explaining up to 36% of Lp(a) variance in European-
descent [5,8,9]. In addition, the hapoltype formed by
four SNPs (rs2048327, rs3127599, rs7767084 and
rs10755578) in this region is also related to the plasma
level of Lp(a) [1].
Researchers tried to explore the association between
the SLC22A3-LPAL2-LPA gene cluster and CAD. Tre-
gouet et al. identified this region as a risk cluster for
CAD in the genome-wide haplotype study (GWHS) inThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the gene cluster was a strong susceptive locus for MI in
the European [10]. However, the research of Qi et al. did
not confirm the association between haplotypes in the
SLC22A3-LPAL2-LPA region and nonfatal acute MI risk
in Hispanics [11].
These contrary data indicate that more large-scale and
independent studies should be performed to confirm the
association between this cluster and CAD and verify
whether this finding can be expanded to other popula-
tions. Up to date, there is no report on the correlation
between SLC22A3-LPAL2-LPA and CAD in Chinese




We performed a statistical power analysis using the PS
program to verify whether the recruited samples could
provide adequate power in identifying the association
between the SNPs and CAD. Under the assumption of
odd ratio being 1.236, and the risk allele frequency being
0.341, as previously reported [1], our sample size with
1012 well-characterized CAD cases and 889 healthy con-
trols can provide a statistical power of 88.0% and 71.2%
at the nominal type I error rate of 0.05 and 0.01 respect-
ively. The power analysis indicated that our sample size
is sufficient for identifying the modest-effect-size SNP.
Characteristics of participants
This case–control study included 1012 CAD patients
and 889 healthy controls. Characteristics of the partici-
pants are summarized in Table 1. Compared with con-
trols, the CAD patients were older, more likely to have a
higher BMI, and to be current smokers.
Characteristics of four SNPs
All the call rates for the 4 SNPs were above 99%. All the
four SNPs tested were polymorphic, with minor allele
frequency ranging from 0.124 to 0.412, and in agreement
with Hardy-Weinberg equilibrium. The linkage disequi-
librium between rs2048327 and rs10755578 wasTable 1 Characteristics of the participants
Characteristics CHD cases Healthy controls P
Sample Size 1012 889 -
Male (%) 68.1% (689/1012) 63.9 (568/889) 0.054
Age 63.74±11.13 59.79±5.63 <0.001
Current Smokers (%) 63.75±5.71 59.92±5.62 <0.001
BMI 23.84±3.27 23.29±3.11 <0.001
Data are shown as mean ± SD or percentage.
Continuous data were tested using 2-tailed Student t-test and categorical data
were tested using a Chi-square test (with df = 1) for difference between CHD
cases and healthy controls.relatively low (D’= 0.43 in cases, and D’= 0.48 in con-
trols). D’ values between other SNPs ranged from 0.94
to 1. The information about the four SNPs was shown in
Table 2 and Figure 1.Allelic association and genotypic association
First, the associations between polymorphisms of
rs2048327, rs3127599, rs7767084, rs10755578 and CAD
were evaluated. OR and 95% CI for each SNP were cal-
culated with the ancestral allele as the reference, and the
statistical significance was defined by the permutation
test mentioned in the method section. There was no sig-
nificant association between any allele of the four SNPs
and CAD (P-obs = 0.23-0.50, OR: 0.92-1.10). Permuta-
tion P values calculated using 100 000 Monte Carlo
simulations were of no significance, either (as shown in
Table 3).
We further examined the association between individual
SNP and CAD risk under additive, dominant or recessive
model, respectively. In the univariate logistic regression,
none of the four SNPs showed significant association with
CAD risk (P = 0.09-0.84), and further adjustment for the
conventional risk factors such as age, sex, smoking and
BMI did not change the results (P = 0.12-0.77). The
results were list in Table 4.Haplotype association analysis
The frequencies of haplotypes from different blocks were
estimated and all the haplotypes with a frequency above
1% were included in the following analysis. In the haplo-
type association analysis, one haplotype was treated as a
single variant, and all the other haplotypes were col-
lapsed into the alternative allele to test its association
with CAD. Age, sex, smoking and BMI were adjusted.
The results were shown in Table 5.
Only two of all the tested haplotypes, TCC (which was
made up by rs2048327, rs3127599 and rs10755578), and
TC (which was made up by rs2048327 and rs10755578),
reached the single-point significance level (P-obs = 0.04
and 0.03). However, the two findings could not survive
over multiple test corrections. The P-values for the two
haplotypes after the permutation test using 100 000
Monte Carlo simulations were 0.33 and 0.29, respect-
ively. Moreover, the overall tests for all haplotypes
formed by the three and the two SNPs did not achieve
significance (P-obs = 0.17, with df = 4 and P-obs = 0.16,
with df = 3), either. Haplotypes TC and TG formed by
rs2048327 and rs10755578 were reported to be the risk
haplotypes in a Japanese sample [12]. However, haplo-
type TG showed no significant association with CAD
(P-obs = 0.41, P-emp = 0.98) in this Chinese Han sam-
ple, as well as haplotype TC mentioned above (as shown
in Table 5).
Table 2 Information about the four SNPs in the SLC22A3-LPAL2-LPA region
SNP Chromosome Gene Minor allele MAF P-HW* Call rate
rs2048327 6q26-q27 SLC22A3 C 0.410 0.78 99.2%
rs3127599 6q26-q27 LPAL2 T 0.124 0.52 99.7%
rs7767084 6q26-q27 LPA C 0.261 0.22 99.7%
rs10755578 6q26-q27 LPA C 0.412 0.36 99.8%
MAF, minor allele frequency.
P-HW*, P value for Hardy-Weinberg disequilibrium analysis in controls.
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common haplotype formed by the four SNPs was TCTC,
and haplotypes CCTC, CTTG and TTTC were found to
be associated with increased risk of CAD [1,10]. In this
study, the most common haplotype was TCTG and the
haplotype CTTG was not found. Haplotypes CCTC and
TTTC showed no significant association with CAD
(P-obs = 0.11, P-emp = 0.64 and P-obs = 0.30, P-emp =
0.95, separately). With the most common haplotype
TCTG as the reference, OR and 95% CI for haplotypes
CCTC and TTTC were 0.77 (0.45-1.32) and 1.15 (0.86-
1.53). Furthermore, the corresponding OR and 95% CI for
haplotypes CCTC and TTTC were 0.47 (0.17-1.30) and
0.694 (0.28-1.74), when the haplotype TCTC was used as
the reference, which could not reach statistical signifi-
cance, either. Data were not shown here.
Discussion
In 2009, Tregouet et al. identified the SLC22A3-LPAL2-
LPA gene cluster as a risk cluster and haplotypes CTTG
and CCTC formed by rs2048327, rs3127599, rs7767084
and rs10755578 as risk haplotypes for CAD in six WhiteFigure 1 LD plots of the four SNPs in the SLC22A3-LPAL2-LPA region.
rs10755578, were derived from the genotyping data from the Han Chinese
correlation between the SNPs was measured as D’ and shown (×100) in eapopulations [1]. From then on, several GWHS have fo-
cused on this hot spot. In a study consisted of 3657
patients with MI and 1211 control individuals, Koch
et al. observed significant association between haplo-
types formed by the same four SNPs in the SLC22A3-
LPAL2-LPA region and MI (P = 0.0005), and found 3
risk haplotypes (CTTG, CCTC, and TTTC) [10]. Later,
Sawabe M etal analyzed rs2048327 (C/T) and
rs10755578 (C/G) in 1,150 Japanese autopsy cases, and
ascertained that haplotypes TC and TG worked as risk
factors for both coronary sclerosis and CAD [12]. In
addition, Shaw et al. found that genetic variants at the
SLC22A3-LPAL2-LPA locus were associated with
decreased early-outgrowth colony-forming units, thereby
increased the risk of MI [13], which may support the
findings in population studies mentioned above. How-
ever, Qi et al. did not confirm the association of haplo-
types at the SLC22A3-LPAL2-LPA locus with nonfatal
MI risk in Hispanics [11].
For gene association studies, repeating previous find-
ings across different populations is essential for explor-
ing the full scape of their pathogenic nature. To date,LD patterns between four SNPs, rs2048327, rs3127599, rs7767084 and
CHD patients (A) and healthy control (B), respectively. The pairwise
ch diamond.
Table 3 Allelic association of four SNPs in SLC22A3-LPAL2-
LPA with CHD in a Han Chinese population
Frequency Allele/Risk OR †P {P
SNP Case Control Ancestral (95%CI) -obs -emp
rs2048327 0.405 0.417 C/T 0.95(0.84-1.08) 0.45 0.84
rs3127599 0.129 0.118 T/C 1.10(0.91-1.34) 0.33 0.69
rs7767084 0.265 0.255 C/T 1.05(0.91-1.22) 0.5 0.87
rs10755578 0.579 0.599 G/C 0.92(0.81-1.05) 0.23 0.53
Ancestral allele was retrieved from dbSNP database.
†P-obs , uncorrected P value. {P-emp , permutation P value calculated using
100 000 Monte Carlo simulations.
OR, odds ratio; CI, confidence interval.
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CAD and the SLC22A3-LPAL2-LPA gene cluster in
Chinese people. Our study for the first time attempted
to explore such association in Chinese Hans. We evalu-
ated the association between four SNPs in this gene
cluster and CAD by examming all kinds of associations
(allelic, genotypic and haplotype). Nevertheless, we did
not identify any significant evidence to link this gene
cluster to CAD risk in this Chinese Han sample. The
genotypic and allelic association between individual SNP
and CAD drawn from our data were consistent with
results from previous GWHS [1]. Whereas, there are dif-
ferences exist between our study and previous studies.
The most common haplotype we found was TCTG in-
stead of TCTC, which was reported in European popula-
tions [1,10,11]. Moreover, we did not confirm the
association of haplotypes CTTG, CCTC, and TTTC
with CAD reported in European populations [1,10]. InTable 4 Assessment of association between four SNPs in
SLC22A3-LPAL2-LPA region with CHD
Without Adjustment† With Adjustment {
SNP Model P OR (95%CI) P OR (95%CI)
rs2048327 Additive 0.44 0.95(0.83-1.08) 0.56 0.96(0.84-1.10)
Dominant 0.84 1.02(0.94-1.24) 0.70 1.04(0.85-1.27)
Recessive 0.09 0.81(0.63-1.03) 0.12 0.82(0.63-1.05)
rs3127599 Additive 0.32 1.10(0.91-1.34) 0.53 1.07(0.87-1.31)
Dominant 0.37 1.10(0.89-1.36) 0.59 1.60(0.85-1.33)
Recessive 0.50 1.32(0.59-2.96) 0.59 1.26(0.55-2.92)
rs7767084 Additive 0.50 1.05(0.91-1.22) 0.19 1.13(0.94-1.37)
Dominant 0.26 1.11(0.93-1.33) 0.19 1.13(0.94-1.37)
Recessive 0.60 0.91(0.64-1.29) 0.60 0.91(0.63-1.31)
rs10755578 Additive 0.21 0.92(0.80-1.05) 0.29 0.93(0.81-1.07)
Dominant 0.84 0.98(0.76-1.25) 0.77 0.96(0.74-1.25)
Recessive 0.10 0.85(0.70-1.03) 0.20 0.88(0.72-1.07)
†P values were obtained from univariate logistic regression model where the
SNP predictor was coded according to three different genetic models.
{P values were multivariate obtained from logistic regression model after
adjustment for gender, age, smoking and BMI.
OR, odds ratio; CI, confidence interval.addition, we did not find any association between CAD
and two haplotypes TC and TG composed by rs2048327
and rs10755578, which was inconsistent with the results
from a Japanese study [12].
There are many reasons for heterogeneity in genetic as-
sociation studies. Ethnic differences in genetic structure
may produce different LD, thereby differences in the sig-
nificance of the association test, which also exist in other
genetic association studies [14]. Besides, differences in en-
vironmental, dietary or behavioral factors may also par-
tially explain the heterogeneity in the genetic associations
across ethnicities [15,16]. Furthermore, different disease
definitions under different criteria may also be partly re-
sponsible for the variation between studies.
To limit the potential influence of factors mentioned
above, we carefully designed and implemented this
study. First, we used an adequate sample with enough
statistical power, to detect the genetic association, there-
fore, the discrepancies between our study and others in
different populations may be more likely due to the eth-
nic differences in genetic structure. Second, we per-
formed multivariate logistic model to adjust several
possible covariates, such as age, gender, smoking status
and BMI. Moreover, we identified the case subjects in a
strict accordance with a generally accepted definition of
CAD and excluded patients taking niacin which could
decrease the plasma level of Lp(a) and/or patients with
diabetes since diabetes status was reported to attenuate
the relation between Lp(a) and cardiovascular risk [17].
Despite our study was well organized, several limita-
tions still exist in this exploratory study. First, as a com-
plex disease, many factors may contribute to CAD, such
as environmental and polygenic backgrounds, dietary
and behavioral factors, hence, the genetic parameter esti-
mates (odd ratios, risk allelic or genotype frequencies)
may be biased. In addition, uncontrolled confounding
factors may lead to spurious associations. Although
many important confounding factors were controlled or
adjusted in our analysis, some potential confounders,
such as lipid level, were unavailable for a large number
of subjects and thus not controlled.
Conclusions
Our study for the first time explored the association be-
tween CAD and the four SNPs in the SLC22A3-LPAL2-
LPA gene cluster in Chinese Hans. We found no allelic,
genotypic and haplotype association between the four
SNPs in the SLC22A3-LPAL2-LPA gene cluster and CAD.
Methods
Subjects
The method we recruited participants was described
prevously [18]. Briefly, all subjects were of the ethnic
Han origin and are not related to each other. Cases and
Table 5 Assessment of association between haplotypes made up of four SNPs with CHD
Frequency
SNPs Haplotype Case Control OR †P-obs {Pcpemp
rs2048327|rs3127599 0.14* 0.36*
|rs7767084|rs10755578 CCCC 0.255 0.246 1.06 0.47 0.99
TTTC 0.123 0.109 1.12 0.30 0.95
CCTC 0.025 0.033 0.71 0.11 0.64
TCTC 0.013 0.008 1.75 0.16 0.78
CCTG 0.128 0.14 0.92 0.40 0.98
TCTG 0.457 0.465 0.96 0.61 1
rs2048327|rs3127599 0.28* 0.60*
|rs7767084 CCC 0.258 0.25 1.05 0.52 1
TTT 0.129 0.116 1.09 0.40 0.98
CCT 0.15 0.17 0.88 0.15 0.76
TCT 0.463 0.464 0.99 0.91 1
rs2048327|rs3127599 0.17* 0.41*
|rs10755578 TTC 0.125 0.114 1.09 0.43 1
CCC 0.274 0.274 1.01 0.95 1
TCC 0.023 0.014 1.82 0.04 0.33
CCG 0.13 0.143 0.92 0.38 0.98
TCG 0.447 0.455 0.97 0.62 1
rs2048327|rs7767084 0.18* 0.43*
|rs10755578 CCC 0.257 0.249 1.05 0.56 1
CTC 0.025 0.032 0.68 0.11 0.66
TTC 0.134 0.117 1.15 0.20 0.85
CTG 0.126 0.14 0.90 0.32 0.96
TTG 0.458 0.463 0.97 0.69 1
rs3127599|rs7767084 0.43* 0.78*
|rs10755578 CCC 0.262 0.251 1.07 0.37 0.98
TTC 0.122 0.108 1.11 0.33 0.96
CTC 0.038 0.04 0.90 0.56 1
CTG 0.579 0.601 0.92 0.27 0.93
rs2048327|rs3127599 0.66* 0.93*
TT 0.127 0.117 1.07 0.52 1
CC 0.405 0.416 0.97 0.62 1
TC 0.468 0.466 1.01 0.89 1
rs3127599|rs7767084 0.35* 0.69*
CC 0.265 0.254 1.07 0.37 0.98
TT 0.128 0.117 1.07 0.50 1
CT 0.607 0.629 0.92 0.22 0.88
rs7767084|rs10755578 0.37* 0.71*
CC 0.264 0.254 1.06 0.42 1
TC 0.158 0.147 1.05 0.62 1
TG 0.579 0.599 0.92 0.24 0.91
rs2048327|rs7767084 0.24* 0.53*
CC 0.257 0.248 1.06 0.49 1
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Table 5 Assessment of association between haplotypes made up of four SNPs with CHD (Continued)
CT 0.152 0.172 0.87 0.14 0.73
TT 0.591 0.581 1.03 0.70 1
rs2048327|rs10755578 0.16* 0.39*
CC 0.274 0.279 0.97 0.67 1.
TC 0.146 0.122 1.27 0.03 0.29
CG 0.130 0.138 0.96 0.72 1
TG 0.450 0.461 0.94 0.41 0.98
rs3127599|rs10755578 0.39* 0.73*
TC 0.125 0.115 1.06 0.57 1
CC 0.298 0.288 1.05 0.53 1
CG 0.578 0.597 0.93 0.30 0.95
†P-obs, uncorrected P value. {P-emp, permutation P value calculated using 100 000.
Monte Carlo simulations.
* Uncorrected P value and permutation P value for a single omnibus test, which jointly estimate a testing all haplotype effects at the position, df = H-1, if there
are H haplotypes at the position.
OR, odds ratio. OR for every haplotype was calculated taking all the rest haplotypes together as reference.
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CAD were recruited from the Guangzhou Military Re-
gion General Hospital and the healthy controls were
randomly selected from several communities in
Guangzhou. CAD was diagnosed if any of the following
criteria was met: (1) confirmed MI; (2) ≥50% stenosis in
at least one coronary vessel at angiography; (3) a vali-
dated history of percutaneous transluminal coronary
angioplasty or coronary artery bypass graft surgery and
pectoris; (4) primarily diagnosed by symptoms and later
confirmed by at least one non-invasive provocation test,
e.g. scintigraphy or treadmill test [19]. Patients with dia-
betes and/or those taking niacin were excluded. Full hos-
pital records were reviewed to confirm the diagnosis. At
the enrolment, anthropometric measures and drug uses
for both cases and controls were collected by well-
trained interns and physicians. Body mass index (BMI)
was calculated using the formula: BMI=weight in kilo-
grams/ (height in meters×height in meters). The study
was approved by the Ethics Committees of the partici-
pating hospitals and institutions. All participants have
signed the written informed consent forms. The investi-
gation conformed to the principles outlined in the Dec-
laration of Helsinki.
SNP Genotyping
Genomic DNA was isolated from peripheral blood lym-
phocytes using the TIANamp Blood DNA Kit (Tiangen
Inc; Beijing; China). The four SNPs rs204832, rs3127599,
rs7767084 and rs10755578 were genotyped using Illumina
Golden Gate Genotyping Bead Chips (Illumina Inc; San
Diego; USA) (http://www.Illumina.Com/), which uses illu-
miCodes, unique 23-bp single stranded DNA oligos, to
correctly identify each DNA as well as the loci being inter-
rogated [20]. First, prepared DNA samples were amplifiedusing universal PCR primers labeled with Cy3 and Cy5
fluorescent dyes, and the resulting fluorescently labeled
PCR product was then hybridized to a Universal Bead-
Chip, which contained randomly assembled universal
beads, each displaying an illumiCode corresponding to
specific loci.
The quality for SNP genotyping was assured by inde-
pendently replicating the genotyping and allelic calls of
30 randomly selected samples. The results from quality
control were in perfect agreement with the initial geno-
typing results. In addition, all the DNA samples for cases
and controls were run in the same batches.
Statistical analysis
Continuous covariates were expressed as meaxn ± SD,
and the differences between cases and controls were ana-
lyzed by independent t-test or Mann–Whitney U test.
Categorical variables were summarized as frequency (per-
centage) and analyzed by Chi-square test. Genotype
coding method of Lewis was used to build additive,
dominant and recessive genetic models [21]. Odds ratio
(OR) and Wald 95% confidence interval (CI) were calcu-
lated using the homozygote of ancestral allele as reference.
The ancestral alleles were defined by the dbSNP database
(http://www.ncbi.nlm.nih.gov/snp). Genotypic association
between each SNP and CAD was analyzed by using uni-
variate (with only SNP included) and multivariate BMI lo-
gistic regression under additive, dominant and recessive
genetic models. In the multivariate analysis, age, gender,
smoking and BMI were also modeled and adjusted. All
statistical analyses mentioned above were performed with
the SPSS 13.0 (SPSS Inc; Chicago; USA).
Prior to the experiment, the case–control design and
the sample size were evaluated by the PS program, a soft-
ware for power analysis [22]. The Hardy-Weinberg
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the SNPs were analyzed by employing Haploview 4.2
(http://www.broad.mit.edu/mpg/haploview). The extent of
disequilibrium was expressed by D’. Haplotype frequency
estimation, allelic and haplotype association analyses were
implemented and then followed by permutation analysis
with 100 000 Monte Carlo simulations by using PLINK
software (http://pngu.mgh.harvard.edu/~purcell/plink). In
the allelic association analysis, OR and 95%CI were calcu-
lated using the ancestral allele as reference. The associa-
tions between all the haplotypes drawn from every two,
every three or all four SNPs and CAD were analyzed, ex-
cept for those with frequency below 1%.
Abbreviations
Lp(a): Lipoprotein(a); CAD: Coronary artery disease; SLC22A3: Solute carrier
family 22 member 3; LPAL2: Lipoprotein(a)-like 2; LPA: Lipoprotein(a); Lp
(a): Lipoprotein(a); MI: Myocardial infarction; apo(a): Apolipoprotein(a);
GWHS: Genome-wide haplotype study; BMI: Body mass index; OR: Odds ratio;
CI: Confidence interval; LD: Linkage disequilibrium.
Competing interests
The author’s declare that they have no competing interests'.
Authors’ contributions
JQ, SR, WL and MX conceived of the project and participated in its design,
revised the paper, and they gave final approval of the version to be
published. YZ, XL, MW, DS and XL collected clinical data and extracted DNA.
XL and JQ carried out statistical analysis and wrote the manuscript. FL and
XF took charge of genotyping, and helped to draft the manuscript. XZ, DF,
HG, DL,Y Y and PO helped to statistical analysis and revised the paper. XL, YZ
and SR contributed equally to this work. All authors read and approved the
final manuscript.
Acknowledgments
We give our sincere thanks to all individuals who participated in the present
study and to the medical personnel in Department of Cardiovascular of the
Guangzhou Military Region General Hospital for their assistance. We are
grateful to Yibing Chen and Jianrong He for revising the paper. This research
was supported by grants from the National Natural Science Foundation of
China (No. 81130052, 81010017 and 31071166 ), Doctor's Launching Project,
Guangdong Province Natural Science Fund (Grant No.10451008901006170),
and Science and Technology Planning Project of Guangdong Province
(Grant No. 2009A030301004).
Author details
1Guangdong Provincial Key Laboratory of Food, Nutrition and Health,
Department of Nutrition, School of Public Health, Sun Yat-Sen University
(Northern Campus), 74 Zhongshan Road 2, Guangzhou 510080, China.
2Department of Cardiology, Guangzhou Region General Hospital, 111 Liuhua
Road, Guangzhou 510070, China. 3Institute of Medical Systems Biology;
Department of Medical Statistics and Epidemiology, School of Public Health,
Guangdong Medical College, Dongguan, Guangdong 523808, China.
4Department of Medical Statistics and Epidemiology, School of Public Health,
Sun Yat-Sen University (Northern Campus), 74 Zhongshan Road 2,
Guangzhou 510080, China. 5Department of Food Science, Yingdong College
of Bioengineering, Shaoguan University, Daxue Road, Shaoguan, 512005,
Guangdong Province, China. 6Department of Nutrition, Guangdong
Provincial People’s Hospital, 106 Zhongshan Road 2, Guangzhou 510080,
China.
Received: 31 January 2012 Accepted: 30 September 2012
Published: 4 October 2012
References
1. Trégouët DA, König IR, Erdmann J, Munteanu A, Braund PS, Hall AS,
Grosshennig A, Linsel-Nitschke P, Perret C, DeSuremain M, Meitinger T,Wright BJ, Preuss M, Balmforth AJ, Ball SG, Meisinger C, Germain C, Evans A,
Arveiler D, Luc G, Ruidavets JB, Morrison C, van der Harst P, Schreiber S,
Neureuther K, Schäfer A, Bugert P, El Mokhtari NE, Schrezenmeir J, Stark K, et al:
Genome-wide haplotype association study identifies the SLC223A-LPL2-LPA
gene cluster as a risk locus for coronary artery disease. Nature Genet 2009,
41:283–285.
2. Kraft HG, Menzel HJ, Hoppichler F, Vogel W, Utermann G: Changes of
genetic apolipoprotein phenotypes caused by liver transplantation.
Implications for apolipoprotein synthesis. J Clin Invest 1989, 83:137–142.
3. Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, Perry PL, Di
Angelantonio E, Thompson A, White IR, Marcovina SM, Collins R, Thompson SG,
Danesh J: Lipoprotein(a) concentration and the risk of coronary heart
disease, stroke, and nonvascular mortality. JAMA 2009, 302:412–423.
4. Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF,
Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT,
Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgözoglu L,
Tybjærg-Hansen A: Lipoprotein(a) as a cardiovascular risk factor: Current
status. Eur Heart J 2010, 31:2844–2853.
5. Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, Parish S,
Barlera S, Franzosi MG, Rust S, Bennett D, Silveira A, Malarstig A, Green FR,
Lathrop M, Gigante B, Leander K, de Faire U, Seedorf U, Hamsten A, Collins R,
Watkins H, Farrall M: Genetic variants associated with lp(a) lipoprotein level
and coronary disease. N Engl J Med 2009, 361:2518–2528.
6. Dahlen GH, Stenlund H: Lp(a) lipoprotein is a major risk factor for
cardiovascular disease: Pathogenic mechanisms and clinical significance.
Clin Genet 1997, 52:272–280.
7. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH:
Apolipoprotein(a) gene accounts for greater than 90% of the variation in
plasma lipoprotein(a) concentrations. J Clin Invest 1992, 90:52–60.
8. Ober C, Nord AS, Thompson EE, Pan L, Tan Z, Cusanovich D, Sun Y, Nicolae R,
Edelstein C, Schneider DH, Billstrand C, Pfaffinger D, Phillips N, Anderson RL,
Philips B, Rajagopalan R, Hatsukami TS, Rieder MJ, Heagerty PJ, Nickerson DA,
Abney M, Marcovina S, Jarvik GP, Scanu AM, Nicolae DL: Genome-wide
association study of plasma lipoprotein(a) levels identifies multiple genes
on chromosome 6q. J Lipid Res 2009, 50:798–806.
9. Lanktree MB, Anand SS, Yusuf S, Hegele RA: Comprehensive analysis of
genomic variation in the lpa locus and its relationship to plasma
lipoprotein(a) in south asians, chinese, and european caucasians. Circ
Cardiovasc Genet 2010, 3:39–46.
10. Koch W, Hoppmann P, Erl A, Schrempf M, Schatke A, Tuerk S, Mueller JC,
Schoemig A, Kastrati A: Risk polymorphisms and haplotypes identified in
genome-wide association studies and their relation with myocardial
infarction. Eur Heart J 2010, 31:801.
11. Qi L, Ma J, Qi Q, Hartiala J, Allayee H, Campos H: Genetic risk score and
risk of myocardial infarction in hispanics. Circulation 2011, 123:374–380.
12. Sawabe M, Tanaka N, Arai T, Mieno MN, Ikeda S, Muramatsu M: Genetic
polymorphisms of SLC22A3-LPL2-LPA gene cluster has direct and indirect
effects on coronary atherosclerosis and coronary heart disease. HUGO J
2009, 4:107.
13. Shaw SY, Cheng S, Cupples LA, Larson MG, McCabe EL, Ngwa JS, Wang YA,
Martin RP, Klein RJ, Hashmi B, Ajijola OA, Lau E, O’Donnell CJ, Vasan RS,
Cohen KS, Wang TJ: Genetic and clinical correlates of early-outgrowth
colony-forming units. Circ Cardiovasc Genet 2011, 4:296–304.
14. Lanktree MB, Anand SS, Yusuf S, Hegele RA: Replication of genetic
associations withplasma lipoprotein traits in a multiethnic sample. J Lipid
Res 2009, 50:1487–1496.
15. Qi L, Hu FB, Hu G: Genes, environment, and interactions in prevention of
type 2 diabetes: A focus on physical activity and lifestyle changes. Curr
Mol Med 2008, 8:519–532.
16. Qi L, Cho YA: Gene-environment interaction and obesity. Nutr Rev 2008,
66:684–694.
17. Qi Q, Workalemahu T, Zhang C, Hu FB, Qi L: Genetic variants, plasma
lipoprotein(a) levels, and risk of cardiovascular morbidity and mortality
among two prospective cohorts of type 2 diabetes. Eur Heart J 2011,
Epub ahead of print.
18. Lv X, Zhang Y, Rao S, Qiu J, Wang M, Luo X, Zuo X, Su D, Feng X, Yang Y,
Ouyang P, Chen Y, Li X, Xiao Y, Ling W: Joint effects of genetic variants in
multiple Loci on the risk of coronary artery disease in chinese han
subjects. Circ J 2012, 76(8):1987–1992.
19. Samani NJ, Deloukas P, Erdmann J, Hengstenberg C, Kuulasmaa K, McGinnis R,
Schunkert H, Soranzo N, Thompson J, Tiret L, Ziegler A: Large scale
Lv et al. Lipids in Health and Disease 2012, 11:128 Page 8 of 8
http://www.lipidworld.com/content/11/1/128association analysis of novel genetic loci for coronary artery disease.
Arterioscler Thromb Vasc Biol 2009, 29:774–780.
20. Pask R, Rance HE, Barratt BJ, Nutland S, Smyth DJ, Sebastian M, Twells RC,
Smith A, Lam AC, Smink LJ, Walker NM, Todd JA: Investigating the utility of
combining phi29 whole genome amplification and highly multiplexed
single nucleotide polymorphism beadarray genotyping. BMC Biotechnol
2004, 4:15.
21. Lewis CM: Genetic association studies: Design, analysis and
interpretation. Brief Bioinform 2002, 3:146–153.
22. Dupont WD, Plummer WD Jr: Power and sample size calculations for
studies involving linear regression. Control Clinical Trials 1998, 19:589–601.
doi:10.1186/1476-511X-11-128
Cite this article as: Lv et al.: Lack of association between four SNPs in
the SLC22A3-LPAL2-LPA gene cluster and coronary artery disease in a
Chinese Han population: a case control study. Lipids in Health and
Disease 2012 11:128.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
